Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5638542 | 0.89 | TSHR (0.46) | TSHRHSD17B10BRD4GAAMGAM | |
| SCHEMBL14499820 | 0.89 | TSHR (0.46) | TSHRHSD17B10BRD4GAAMGAM | |
| SCHEMBL5638546 | 0.89 | TSHR (0.46) | TSHRHSD17B10BRD4GAAMGAM | |
| SCHEMBL18257698 | 0.81 | TSHR (0.39) | TSHRHSD17B10BRD4GAAMGAM | |
| SCHEMBL5639358 | 0.81 | SLC6A12 (0.46) | TSHRHSD17B10BRD4GAAMGAM | |
| SCHEMBL5639352 | 0.81 | SLC6A12 (0.46) | TSHRHSD17B10BRD4GAAMGAM | |
| SCHEMBL14499819 | 0.81 | SLC6A12 (0.46) | TSHRHSD17B10BRD4GAAMGAM | |
| SCHEMBL12674588 | 0.78 | ALOX5 (0.38) | TSHRHSD17B10BRD4GAAMGAM | |
| SCHEMBL5640893 | 0.78 | TSHR (0.36) | TSHRHSD17B10BRD4GAAMGAM | |
| SCHEMBL5640897 | 0.78 | TSHR (0.36) | TSHRHSD17B10BRD4GAAMGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2598485-B1 | NOVEL MONTELUKAST 4-HALOBENZYLAMINE SALT AND METHOD FOR PREPARING MONTELUKAST SODIUM SALT BY USING THE SAME | DONG KOOK PHARM CO LTD (KR) | 2015-04-22 | — | — | EP | disclosed |
| US-20130184464-A1 | NOVEL MONTELUKAST 4-HALOBENZYLAMINE SALT AND METHOD FOR PREPARING MONTELUKAST SODIUM SALT BY USING THE SAME | DONG KOOK PHARM. CO., LTD. (KR) | 2013-07-18 | — | — | US | disclosed |
| US-20130184464-A1 | NOVEL MONTELUKAST 4-HALOBENZYLAMINE SALT AND METHOD FOR PREPARING MONTELUKAST SODIUM SALT BY USING THE SAME | DONG KOOK PHARM. CO., LTD. (KR) | 2013-07-18 | — | — | US | disclosed |
| US-20130184464-A1 | NOVEL MONTELUKAST 4-HALOBENZYLAMINE SALT AND METHOD FOR PREPARING MONTELUKAST SODIUM SALT BY USING THE SAME | DONG KOOK PHARM. CO., LTD. (KR) | 2013-07-18 | — | — | US | disclosed |
| EP-2598485-A2 | NOVEL MONTELUKAST 4-HALOBENZYLAMINE SALT AND METHOD FOR PREPARING MONTELUKAST SODIUM SALT BY USING THE SAME | DONG KOOK PHARMACEUTICAL CO., LTD. (KR) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012015255-A2 | NOVEL MONTELUKAST 4-HALOBENZYLAMINE SALT AND METHOD FOR PREPARING MONTELUKAST SODIUM SALT BY USING THE SAME | DONG KOOK PHARM. CO., LTD (KR) | 2012-02-02 | — | — | WO | disclosed |
| US-20080214822-A1 | Process For the Preparation of a Leukotriene Antagonist | MEDICHEM, S.A. (ES) | 2008-09-04 | — | — | US | disclosed |
| US-20080214822-A1 | Process For the Preparation of a Leukotriene Antagonist | MEDICHEM, S.A. (ES) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214822-A1 | Process For the Preparation of a Leukotriene Antagonist | LTB4R2, LTC4S, LTB4R | TSHR 3701/4885HSD17B10 526/4885BRD4 4471/4885 |
| US-20130184464-A1 | NOVEL MONTELUKAST 4-HALOBENZYLAMINE SALT AND METHOD FOR PREPARING MONTELUKAST SODIUM SALT BY USING THE SAME | HRH4, TST, HCLS1 | TSHR 3007/4885HSD17B10 483/4885BRD4 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.